Arcus Biosciences (RCUS) Cash from Financing Activities (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Cash from Financing Activities of $3.0 million for Q1 2026, down 97.89% year-over-year from $142.0 million in Q1 2025, and down 98.95% quarter-over-quarter from $286.0 million in Q4 2025.
Arcus Biosciences (RCUS) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Arcus Biosciences' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 97.89% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $349.0 million (up 83.68% YoY), while the FY2025 annual figure was $488.0 million, up 76.17% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $3.0 million, down from $286.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $286.0 million in Q4 2025, with the low at -$2.0 million in Q4 2024.
- The 5-year median for Cash from Financing Activities is $8.0 million (2025), against an average of $49.1 million.
- Peak annual rise in Cash from Financing Activities reached 22800.0% in 2024, while the deepest fall reached 166.67% in 2024.
- Arcus Biosciences' Cash from Financing Activities stood at $11.0 million in 2022, then slumped by 72.73% to $3.0 million in 2023, then plunged by 166.67% to -$2.0 million in 2024, then soared by 14400.0% to $286.0 million in 2025, then plunged by 98.95% to $3.0 million in 2026.
- Business Quant data shows RCUS's Cash from Financing Activities at $3.0 million in Q1 2026, $286.0 million in Q4 2025, and $8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 16.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.00 Mn |
| Jun 30, 2026 | 16.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Dec 31, 2025 | 286.00 Mn |
| Dec 31, 2025 | 286.00 Mn |
| Sep 30, 2025 | 8.00 Mn |
| Sep 30, 2025 | 8.00 Mn |
| Jun 30, 2025 | 52.00 Mn |
| Jun 30, 2025 | 52.00 Mn |
| Mar 31, 2025 | 142.00 Mn |
| Mar 31, 2025 | 142.00 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Sep 30, 2024 | 48.00 Mn |
| Sep 30, 2024 | 48.00 Mn |
| Jun 30, 2024 | 2.00 Mn |
| Jun 30, 2024 | 2.00 Mn |
| Mar 31, 2024 | 229.00 Mn |
| Mar 31, 2024 | 229.00 Mn |